Previous Close | 482.28 |
1-Year Change | 12.45% |
6-Months Change | 1.68% |
3-Months Change | -2.3% |
Moving Avg (50d) | 438.47 |
Moving Avg (200d) | 459.82 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 124.3B |
Beta (3-Years) | 0.61 |
Revenue Growth (ttm) | 10.96% |
Net Profit Margin (ttm) | 35.94% |
Return On Assets (ttm) | 15.97% |
EPS (ttm) | 13.32 |
PE Ratio (ttm) | 36.21 |
Dividend Yield | % |
Asset Description: | Vertex Pharmaceuticals Incorporated |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-12-24 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
472.634 | 458.166 | 448.52 | 434.052 | 409.938 | 385.824 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.